0001387131-20-009724.txt : 20201109 0001387131-20-009724.hdr.sgml : 20201109 20201109162445 ACCESSION NUMBER: 0001387131-20-009724 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20201109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201109 DATE AS OF CHANGE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 201298058 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_110920.htm CURRENT REPORT
0000887247 false 0000887247 2020-11-09 2020-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

     

FORM 8-K

     

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 9, 2020

     

 

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-26372   82-0429727

(State or other jurisdiction
of incorporation)

   (Commission File Number)  

(IRS Employer
Identification No.)

 

11682 El Camino Real, Suite 300

San Diego, CA

   92130
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 997-2400

(Former name or Former Address, if Changed Since Last Report.)

     

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADMP   NASDAQ
Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   
 

 

 

Item 2.02 Results of Operations and Financial Conditions

 

On November 9, 2020, Adamis Pharmaceuticals Corporation (the “Company”) announced certain financial results for the three and nine months ended September 30, 2020. A copy of the Company’s press release announcing this information and certain other information is attached hereto as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits

 

 

Exhibit No.   Description  
     
99.1   Press Release issued November 9, 2020.

 

 

   
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ADAMIS PHARMACEUTICALS CORPORATION
     
     
     
Dated: November 9, 2020 By: /s/ Robert O. Hopkins
  Name: Robert O. Hopkins
  Title: Chief Financial Officer

 

 

   

 

 EX-99.1 2 ex99-1.htm PRESS RELEASE ISSUED NOVEMBER 9, 2020
 

Adamis Pharmaceuticals Corp. 8-K 

Exhibit 99.1

Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update

San Diego, California – November 9, 2020 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update.

 

Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated,

“We are excited to have US WorldMeds in full control of our SYMJEPI product now that the transition from Sandoz has been completed. We expect to see the full impact of this transition going forward and I expect 2021 to be the breakout year for this product. We and our commercial partner eagerly await the FDA’s decision on our ZIMHI NDA which has a target PDUFA date of November 15th. We remain very excited about the remainder of this year and beyond.”

 

Product Updates

 

SYMJEPI (epinephrine) Injection

On July 1, 2020, Adamis’ new commercial partner, USWM began promoting SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products through its field sales force in the U.S. USWM expects to focus its sales efforts on the high-prescribing allergists, pediatricians, and primary care physicians. The transition of sales and distribution from Sandoz to USWM was completed on October 31, 2020 and now USWM is fully responsible for sales and distribution of SYMJEPI.

 

The company’s Australian partner, Emerge Health, which was acquired by Chiesi Farmaceutica in June, continues to work through the regulatory process with the Therapeutic Goods Administration (TGA) in Australia and the company expects a decision from the TGA sometime in the first half of 2021.

 

ZIMHI (naloxone) Injection

The FDA has provided a target action date (PDUFA) of November 15, 2020 with respect to the company’s resubmitted New Drug Application (NDA) relating to ZIMHI. The company continues to work with its commercial partner, as USWM prepares for the commercial launch of ZIMHI.

 

Tempol

Since licensing this product, the company has made some progress on the development of Tempol. Unfortunately, few therapies have been successful so far for the treatment of COVID-19. In preliminary results from a study in collaboration with Stanford University, Tempol inhibits the release of multiple cytokines from activated immune cells of COVID-19 patients. This new data now provides the additional scientific rationale needed to conduct clinical studies in early COVID-19 patients with Tempol. We are currently identifying sites that could conduct this trial. With the additional data from this study, the company continues to explore its options for government and other forms of funding to potentially support additional testing of Tempol.

 

 
 

 

 

Discussions with various groups continue to evolve on the funding and design of a large clinical study to examine the effects of Tempol for the treatment of radiation induced dermatitis. One of these groups, which was previously under the direction Dr. Stephen Hahn (current FDA commissioner), conducted successful clinical studies of Tempol for the treatment of radiation induced alopecia.

 

Drug Outsourcing Facility

Year to date, sterile and non-sterile revenues from the company’s wholly owned drug outsourcing facility, US Compounding (USC), were adversely affected by slowing demand due to the COVID-19 outbreak. Revenues decreased by approximately 21% for the nine months ended September 30, 2020, compared to the same period in the prior year.

 

Third Quarter Financial Results

 

Revenues were approximately $4.3 million and $5.9 million for the three months ended September 30, 2020 and 2019, respectively. This decrease in revenues of approximately 27% year over year was primarily due to the COVID-19 pandemic which has adversely affected revenues from sales of USC products, in part due to reductions or cancellations of outpatient or elective surgeries and other medical procedures and reductions in office visits to physicians' offices, healthcare facilities or clinics by patients, and the resulting decreased demand by USC’s customers for certain of USC’s products.

 

Selling, general and administrative expenses for the three months ended September 30, 2020 and 2019 were approximately $5.8 million and $5.3 million, respectively.

 

Research and development expenses were approximately $1.7 million and $3.3 million for the three months ended September 30, 2020 and 2019, respectively. The decrease was primarily due to completing work on ZIMHI and a decrease in development costs of our other product candidates.

 

Cash and equivalents at the end of the third quarter was approximately $12.4 million. This amount includes proceeds from an equity offering completed in September which provided net proceeds of approximately $10.7 million.

 

Targeted Milestones

●FDA approval and U.S. commercial launch of ZIMHI;
●Apply for government and other forms of funding for Tempol trial in COVID-19 patients; and
●Ex-US partnerships for SYMJEPI and ZIMHI.

 

 
 

 

 

Conference Call

Adamis will host a conference call and live webcast on Monday, November 9, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of 2020 as well as provide an update on business developments and activities.

 

US Dial-in (Toll Free): 1-855-327-6838

 

TOLL/International Dial-in: 1-604-235-2082

 

Conference ID:  10011804

 

Webcast:  http://public.viavid.com/index.php?id=142367

 

In addition, a telephone playback of the call will be available after approximately 5:00 pm PT on November 9, 2020.  To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN number 10011804.

 

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis.  Adamis’ naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review with a target action date of November 15, 2020. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma and COPD.  The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States.

 

Adamis Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the impact of the COVID-19 outbreak and overall economic outlook on the company’s present and future operations, employees, suppliers, supply chain, manufacturers and commercial partners; the timing and results of the FDA’s review of the company’s resubmitted NDA for ZIMHI; the company’s beliefs concerning the results of studies or clinical trials that the company has conducted relating to ZIMHI or its other products or product candidates; the company’s beliefs concerning its ability to commercialize ZIMHI and its other products and product candidates; the company’s beliefs concerning the success of the transition of commercialization and marketing of its SYMJEPI products from Sandoz to USWM; the company's beliefs concerning the ability of its product candidates to compete successfully in the market; the company's beliefs concerning the safety and effectiveness of SYMJEPI, ZIMHI or its other products and product candidates; the company’s beliefs concerning its commercialization strategies; the company’s beliefs concerning the anticipated timing of any commercial launch of its ZIMHI product; the company’s beliefs concerning the timing or outcome of discussions with the FDA or others concerning the design and funding for trials relating to use of Tempol as a therapeutic treatment for COVID-19 or radiation induced dermatitis, or the timing or outcome of any such trials; statements about strategies, objectives and our future goals and achievements; future financial results of the company and its subsidiaries; future development and regulatory actions concerning the company’s product candidates; the timing and progress of current and future clinical trials or studies; expectations and goals for future growth, including without limitation future growth in revenues from sales of compounded sterile pharmaceutical formulations; anticipated commencement and completion dates for clinical trials; product development timelines; anticipated dates for commercial introduction of products; guidance regarding future periods; and other statements concerning our future operations and activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis' actual results to be materially different from these forward-looking statements. There can be no assurances concerning the timing or outcome of future action by the FDA relating to our resubmitted NDA for ZIMHI. In addition, there can be no assurance that the FDA will conclude that the company’s resubmitted NDA satisfactorily responds to the matters raised in the FDA’s previous Complete Response Letter, that the FDA will approve our resubmitted NDA relating to ZIMHI, or concerning the timing of any future action by the FDA on our resubmitted NDA. The FDA’s review processes can extend beyond, and in some cases significantly beyond, anticipated or target completion or action dates due to the timing of the FDA’s review process, FDA requests for additional data, information, materials or clarification, difficulties scheduling an advisory committee meeting, FDA workload issues, extensions resulting from the submission of additional information or clarification regarding information already in the submission, issues relating to the COVID-19 pandemic, or other reasons. We may not achieve one or more of the target future milestones described in the press release either within the anticipated time periods or at all.  In addition, forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to support such activities and continue our operations and planned activities.  As discussed in our filings with the Securities and Exchange Commission, we will require additional funding, and there are no assurances that such funding will be available.  Failure to timely obtain required funding would adversely affect us and could require us to materially reduce or suspend operations or one or more clinical trials or other product development activities, or delay or prevent our ability to realize the results contemplated by such forward looking statements.  In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  You should not place undue reliance on any forward-looking statements.  Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2019, and our subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Except to the extent required by law, any forward-looking statements in this press release speak only as the date of this press release, and Adamis expressly disclaims any obligation to update any forward-looking statements.

 

Contacts:

Mark Flather

Senior Director, Investor Relations

& Corporate Communications

Adamis Pharmaceuticals Corporation

(858) 412-7951

mflather@adamispharma.com

 

 

 

 

 EX-101.SCH 3 admp-20201109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 admp-20201109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 admp-20201109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 admp-8k_110920_htm.xml IDEA: XBRL DOCUMENT 0000887247 2020-11-09 2020-11-09 iso4217:USD shares iso4217:USD shares 0000887247 false 8-K 2020-11-09 ADAMIS PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11682 El Camino Real Suite 300 San Diego CA 92130 (858) 997-2400 false false false false Common Stock ADMP NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Nov. 09, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2020
Entity File Number 0-26372
Entity Registrant Name ADAMIS PHARMACEUTICALS CORPORATION
Entity Central Index Key 0000887247
Entity Tax Identification Number 82-0429727
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11682 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 997-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADMP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports admp-8k_110920.htm admp-20201109.xsd admp-20201109_lab.xml admp-20201109_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "admp-8k_110920.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "admp-8k_110920.htm" ] }, "labelLink": { "local": [ "admp-20201109_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "admp-20201109_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "admp-20201109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMP", "nsuri": "http://adamispharmaceuticals.com/20201109", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "admp-8k_110920.htm", "contextRef": "From2020-11-09to2020-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adamispharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "admp-8k_110920.htm", "contextRef": "From2020-11-09to2020-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001387131-20-009724-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-20-009724-xbrl.zip M4$L#!!0 ( !:#:5'E])6_20, +8, 1 861M<"TR,#(P,3$P.2YX MU;>E=,\G40,/8)45/"6X[LU!P$/1$CYJ.7<]O%9__SR MTD&G)^_>(O-KOL<875!@80.U18 O^5 Y=3V;'6<[?=)O_QS^073U^*1&5_I#VG[J/:L[%GV!W^T\95,%8X@(,F^"JY8S5UUZ MX HY\O9K-=_[U>WT,YR3 QL31OE]%=ROU^M>MEM"5Y"3@62E](%GMP=$P539 M[-(U>,J5)CQ8P(=Z2I@''WKYY@*45D*/F;#X/=KN.;C M [^$)PJ/"(FGE"%1@TRZV*B@**E7X298#<7Z*0952[-E$%"$E$5 MCXF,2 ")I@%AMF^CC.C[M;J9/081<'TA9-2&(4F8/8L&W2'JFF M*5=(C?C*H*Z[3///0$<$F=0:BGW")0_;$/;WS:WC3E0X<[J-B=D);&>BY.U@ M8NV57N5"O42R"SQC;VI@[0?BA6/(\E<2/6!:E9%7NEG]FNQN)]/:P<_""P^U M]*R0QP7'W%S7D@:;M&ULS9U=;^.X M%8;O"_0_L-Z;%AC'<8(MD.S,+C*>9&%L-DECSVS;1;&@)<81(I,!)2?VOR\I MB;)$\DA*BI+,148COH=Z*3XAJ0]2'W_:;5+T0GB6,/II-#TZ'B%"(Q8G=/UI M]'4QOEC,YO,1RG),8YPR2CZ-*!O]]..?_X3$S\>_C,?H*B%I?(Z^L&@\IP_L M!W2#-^0<_4PHX3AG_ ?T#:=;N8==)2GA:,8VSRG)B4@H#WR.OC_Z?H7&XP'9 M?B,T9OSK_;S.]C'/G\\GD]?7UR/*7O KXT_94<2&9;?(<;[-ZKR.=\?53QG^ M,4WHT[G\M<(90>)DT>Q\ER6?1HVCOIX>,;Z>G!P?3R?__/5Z$3V2#1XG5)ZT MB(Q4E,S%%C<].SN;%*E*:BAW*YZJ8YQ.E)TZ9Y&:=.@;3K+D/"OL7;,(YT6= M]QX&@0KYO[&2C>6N\?1D?#H]VF7Q2)W\X@QREI)[\H"*8I[G^V?!499(#$;5 MOD=.'NQF4LXG,GY"R1KG))8'.I,'FOY='NB[:O=>YLZB5;RI;<\;-LF;5"CDJ(K0\=?% MZ,="@WY7JO]\G!QR<5;=8CBTW1":+T6^EG*TDUU5MLV4JNMF6A!5;3&DU[22 M(*GQ4LT7XO"QM'"5XK6E$%JZJXJVVE(UW4H,HJIMCO2ZKC5(BOQ6]A>213QY MEL/\KM*T9,ZKWF+2(*"A"0L$TQC,0T/KM:F_)^M$=CG2B+SZ)7)G1\,&Z%UW M!IVV]=[!*@X"G2$.P?ZC&83J**\T75"ZQ>D]>6:\"Z*VS#4[-I,Z,DU-4*18 MC(& E%I4BKUR\8^MN+8G/-WWHF$H7=,!6-4!T61!,6+W!F)2RT,@9)D&&[BZ):'"Q(NL.!+!5A2,9Y MY:GQ(*.')$/IFB' JDZ/)@N*&[LWD)A2C@I]**A8?[(%CJ[$%OC]GZF2^@ M"P*7'G/&D^!2WL+%:Y]T2?,DW\N7]6ZVFQ7AEB*:$E>$0.84&7IZ$$0 IG02 M2AF2.E0*/=:_>MI <_FJ)%@H7>:6 [O)-@MM34 \6(T!3!RTQ9NK'KF8B;:* MXW1.8[+[A>S!TADZMV0 -MMH:** V+ [ ^"HQ*A0(R'WB,<=3S:8[Q=)U--Y MF$*W@$!&VX3HJH 0 :P!C%1JM)C/_/L, M"0BS(3X!V%JA'\IW7A"34XB*#)#,P2-W%W$L3E=6_7.=4#(%SX)5ZY:Q#KMM MLBS"@'B"W0$45@L7UE0Z)R^ MH<"G_M$Y'8K.:=#HG+X+'5'] ;0[,[%YRY?LU?9J.*CT HYIU8K-018>-(:W M/F1D@!SGR!#_L!3#KEM^Q]E+0B-X0 W)O6 #F+:RHVG# \ANL(^B>KBLXORC M5 W<>_]@E,Q/B],V:6]N2DUXJ+2-]38TI=H_&'H2L?C%@GN&GI[J8J6VP=IBHW$H- P>;(G*I< MWFTI17XJ6_+*"09:AW:RLZJVF*IKNI$61D6;AHQZ+O[&A<;?'[5V04 M?O7 E+BJ;\BC]?KI"1V1OT1IJS'E^W4W?P*B&( M.M;=&-VW2O=2I[_Q)!?'G['-9DNK9T:V-Q4!G:NZ[K2IZMTJ"H*!+FX%BP-(F2/*'K7\7%*D^PK6PVD2LL8(.*"5,1!!"@+9V&@Q II1<4[CB1 M0!)1'<4T1;E4$K]]>+". KK$KM#H-ZP0@95!H-)K3T=&!(RC1@0J0U 1$P(\ M\RS;$OXFA"PAGD "S0,X&?H0H8),]J)5!OHG;$&BK>@W]].3U3+)4]MEJ"EQ MUDL!YNH^2DL/@A# E$Y$D8;8 YJ>_'7U-Z2BO$!PPY8EI6 ME2L4.BPJ&BR2((" ?>E,W#!425&I];?>5LNRI5!:NBL,K+84 *W$(*K>YLAH M"%HU[K43N-Q%C\(: :9&V&6N.P.;2;U#:&J" *'#F''A4DF1TOJ;&G'HRM;] M@X.UM\'!NF=PL YQ<+ >.CA8>QXOY$T_86R5[H@.&.4Q.4=&-MSIVZ]V_=R M>FRW7\T!Q$% -<0A\(*.#!H_R2BDPJK[9QYY^L;2+C<\@/8 M;'.CB0+BQ>X,X*06HU+M1<1GF=!)H3^26-Y(5\P3FN'(*EAN2NIWUVF=;G>]JT 8'4:1"< MX5G'R 5OL"++\\(W?"8&8FO6\::ZIG*__(UAT5P!IY8$!(G-5\*%G5O!,V]>\156YCG9 M@/,N^D-<<334O**I3Q\$4P--ZF058>W+\"(0R4C_*S,UE_J'!X MD>-QL\6@ M-FQN*((@!;0%#9J;7T[PN3+@=I4FT57*,'Q7IJ5QO!Z@:4];"O @"(@#TQ6T M & A1(72(P6?,7WBV^<\VM]Q%A$BW^C*ZO:K[Z[=P&BWY+RI2&VF!H4&1-M; M_ (<'K) C3P^-/HP_[< Y8OK/OG MSS\E[N?\EV8SZ7$0V5GR3J7-OARI-\DGEL-9\AXD:&:5?I-\8:+P1U2/"]!) M5^53 1;<%\N&SY+71Z^'2;.)J/8+R$SIS_?]3;43:Z=GK=9L-CN2ZHG-E'XT M1ZG"53>PS!9F4U=[WE[]+(N?"RX?S_RO(3.0.%C2G,T-OVALM3H[.5)ZW#IN MMSNMOS_>#-()Y*S)I8>60F-=RM=25:YS>GK:*K]=FQY8SH=:K-LX::W=V=3L MON41^RU/##\SI7LW*F6VC'EM,TG0PO_77)LU_:%FY[AYTCF:FZRQAE\2U$K M/8P2_]?%;M,JRUC.S73"=,Y2*"Q/F?#!RUO>LM55KFLZM\LZ)AI&%PV6Y5/7 MU'&[TVF?^H9>[1C9Q=1U4<-]#VLDK1TGIAH,2%OJOG$'=HK W+J>!=FZ(M_^ M_W+3&.=*&0$#Z=%8 M/;4RX"W/PG\HH33;G17_5^[0M[*YRZ&QFJ5V79]@0Q!E*]^ZC11.@/MN*_K8CK=B>%A]UU9M*9,NXJ:Z82+3?A'6N4A M1BL>*N#H-B[7Q(]D>NF\R+PG/<'&U5#W3)!4.Q18*]70TH8[(?6 M2.Z_D=Z2A .U)+&X0XT5YF[[&M$! Z,D>Q/*=D'%+X ZM_)( M@?>X29E8^M5SQTP<>H4Y%CQ)OEHK\P7 _P>81J/?,L:")TEA:R228.\66N^X M%!UGPM98\"3):YU($O+7TG*[\%,-GXI\^/W!["[Q0RLL:9*$-22*D/#ZB86T M?BHE1GG?$DN:)$^-B2.DW76J-!-]F<'\ RQBN ],L;Q)\M.H/$+@=YKG3"\& M/*T?1@YMLSYPV/N++ZAS=584[0Q==E46'^IJ"V*"0Y*K/D$X8FLLL<]#,ZL\-E]")!:32'#T?11>& MB,P7!?_X>?"/\?!)%WW<=;_:!F@?GOH#$6 M/$D>6R.1'GMY';K5=UH]\>5*KCKV!R6P 2!,;^-BZ:.PNA' ]/RU)98Z8:I; M+8Z>]ITREHE_^;3NGK/:'DN>,.F-":5Y:+GL _[A1VB!TYX)EC))GELIAP:L MC[8&%N[*NQ98K"3):Y48$JHWRL^S3)2,/ND]M,+2),HME^./ M[HY22/+%> MZ$O@WS>F /W<*%24PL:")&7$BJ89>2 MW'"XZ!P/'_Q^H,"XL>;:LA[)EB\)%EAI1S24>)Z MGDZ8'$-X'46U)18S2988$T<\)H]18_+XF6,R2;88$D5*>+G"W9UCMT/!QRR\ M6RY: +U_B))[1"K-3L5R0Y/?X:[STIN>^U -/V"*Q4ZS)30FCP9XD7$+V=*Q M'I=,IBX=V^S@"^3W]:6P8:#9,XH433B)\!6$^"#53 Z &24A6R8(L7F$8!%L M+ CG+FOD$@;BBQ*%8Z7+Q:LZ<#X$3+'@">=/\(Y9MO(S%H50"6P4"";/4,L:L)UNI72"%%?YZ#';K![K]7,3E8[ M6F/( P6PZ E7XT:E4H9@_GT__7*G7Y1_A37Z70V$\(,B:5](DJ9^8A^_8X:E3)C!5L@BA'S%Y*,NIC9=W&F5 M OBI&K,Y_Q!I%+(";& (<]MGH:!\X*#RW&^54NGC8.*DF]O"EB^,=5Y&'SM$ MRV$#1+EI%2&<]$[)?-_,!MG5XAY&H/V"B0>8VRO7W&/\Q@E1'!LETK?N-_^???NB/_ 5!+ P04 " 6@VE1-QKDU!\3 \ MD $@ &%D;7 M.&M?,3$P.3(P+FAT;>T];5?:RM;?NU;_PUSN.G?9]2^<1_#S]^.!APZ =]3?8Y M,>#<+J;3]_?WJ?MLRG+Z::50**3'HD_"[50E4A-^"/)0,KGJZ*QZ)>9]%3G?*W^^3P":RTQ'/6?X3NZ*@%3"9."_ MJ@GLG)2!3PXV:J9.QG4RNB7MIPN$R>^> J%)%IF40VTG%1B"]QI%[(CU37B>FIB?@"^IZ/A@!.DQ!5'^0*;[!\X<1N2+3 M;Z??4UVT]"AQD)P-"?5YY5I]?O46!\_0I4/Q>=ALX+.E+U,!@8?#*YB3P]D4 M?$BSMJ5AL*01@_R61;+F"/"_]%@ZS^>125TF@W8N<7-(,!LYY-!3XR+T\8'Y M3?,H!+0(^*Y-B$3A,4%V>C:.F>U9P@-V I9QF;=BK%0,S"TGT/QT'BS2& 8U M@+1"3&M(SR[ MD_#^#="9GB,T\VG[: H%_N9M'HUN53<9 +F/A %(8H/V MX:,&QHLX0"RSL?ETYWO0/;PXKW6J%=3NE#K5]D&Z"_,6L**G_YK$MJOEBU:M M4ZNV4>F\@JH_RZ>E\Y,J*C?.SFKM=JUQ'O<,W!6,>QX_,!M #LXM:*RDRBFD M0I1:^#MH#Z.2XZY! +9AV%AWJPN9A/P,_33_\[PUT"S#P#8#M?=_9,7L[X@CTP^? V"%YEEBD![W?!BSV7]"N#?K.%-V MCT5<7X:];!"54(,XAS@7 ^(8)P7_N-Y$+OZ:I=43-/_O!JK%<:-UAMSA(HP1 MJ50ALR,SQ&2R8FDC$=&+1/U*FR:SL[3V=_7K[G@\R5<:/W8!W$N3FB"^Q&$^ M65_,'Z8+N:3+[_H<@UH]',/\32J]>;JV0/;&^DF(5%K5\PYJ59N-5F?3(ZOF M1:M]40)R.PT$458'0BF7T4H6-5I(V=G2/Z'&,>J<5O^.,"40*D[#Q%*Y(^:@ M%+*YOV 2HBJ K!YRB&TY'&WYGPF&C(\PCL@=(/":B?ZI^*C[:&7>*@PC82 M@".]U[OG>H]$'XE$5TCZ-\#\SHV4H'6B68[J]V_?/'M]TX(LTPO(G#4J4$^3AJGI9:9Z5R]:)3 M*Y>^MB%-;X$O+'5DGOZP2F^PM]RJCK'&Y=Z),,>SN2/,4-LFFB@SZXB:J#S M8)F=3W%.)>:X:68O@_9QT7X^F=R 49Q&P\MF-L1>KKII%&)-5J/L42/L2L?, M(*EA!NF)BCW35V5.7VLF*+GMZ7F;@_,KNUO/94N/4%]2SE=O.M^Z$WH][Z%7H!,B%6+@>_#MJV294;[@>:OG9EC3Q7K!6JWHLOX* M(=N;$[)C:A!8$8BGPB5J;_P;[YP4[D['1FP.888S<9A)JKO9/?5=.#9#.+)S MPM'!XYJW-:I)[7Y(4HQOE[V+S*7>-W.Q24H$ 8G#O)K,Y-3"GKJT Q\A.7X8 M^/H.!9BS.=&*--?(S!<68]*_E5Z M^'S.EZWAD#)Q]A()>XA/(&R,P#T:HY5TW2&,>3^^0JJOA+M@=C?Y?ID?FZ6+ M;FPN. 1YXE!1=O,JJAJHC(?4M"#-Q4:$(]Y>*CP>/S(Y-7QRI3ZKWP[O!D?U M[!HGIR8.VR,*/C&;B:XL+M0?IH=T_CJ1*L.O#:=CW9OA/#^I9ZWSDZK2RCV_ MX!O!\QEJX#A06J&D;ZTL0VK8;&0PTW":D*M"S!*1(BO#6_.T6K6SU7S<4UK MGS@LEU83H77G-ID-36Y\.A_(;W(OH#U$"TIA$=3H02A& MV/]HK!POJT'ND!"\3P_NF6Q2*+MA&[&S"O]__IU7E;U]!M -8@\LDR!3)G7; M(H4V1B+,1M@A&"R&#N%QB'GRW9IPCB7H&6V0G*/;;.L<<]V,(]0+X@.AR._D M/T68H"5/7/%(_FJ!F#;%K!\J$FEG/5W;L8:U6AQD+^($ZUG82ZJYU4.WS9.G MK6/+ 9KE+$5AQOOHF400I9[8.3+[1$=M$66@KYAQ",#%/G]J:3/I?,T][DV4I0'A!@/1\0A&W;L6R'BC)EUQJC+C&L>Z$$HE'H!LHG MZZA'#6%<*0-+RXFI@W)P"S$Z'!DVPZBHW3&TQ0A!)\0D#L0H-1/&CF3Y%)52:LHE M]U-Q?=O5+^7TVRD711067Q!\>>3N_!,ORQ<]:,'SH#\W,"/@4G MA>R1PT9"[<%PB,>$4$[=\4R T/TV)!\PD +DDL;1EK*'RL@8&CUO M@@BOT52\;'772]A;78*H R-M"% TD$ZS?P:.$KRE$6XW;D[&E_6!T>_PYX?? MJ]B-97K^D-&(D]FS28#S=6>Q;"64'$XJ:L!05,>:#,_GS40NDW)[OEN*S2+L MK2[!HJ6H>I:BZ1#AS<4C^O(9(!$L.XU>+RIA/SX=\3[^U;9VUAMI1-/U%UH. MF$Q2"\SFT5A#R>E)=:O[Z0$[XHKNS)BX ][-R681]E:7(&H?94%M:XR-B/.H M4?FRU[WHZ>W!1?5/VI0EXOXG+$N6)'-;VA,LBS?@?V-#(.:(<98DNG4DXA!] M;DV@ARP.*=+:>W6EX((LE8K>1BG&WU-[@1IYTRW*ZT% 3JD9W"0.WT26WU%3 M'-]ZB=QUQ"5K[M-UV@!I!F8L)ML0-JEYHC?NA/(#ZZ#LKGD='"PWT=J38=4@ELZW; MG?AD M),X37 L!UZY?Z7%=S$11N](JA0=8E]_X4>VB39L_20S;K(LX$X M-=]E[6W+6F'!ROF1J5TI?8N2/?F$P,7//FWQL5X?N79RUTW^%8I9+-H M2ZC+WK[G;][L.5M=:RGF L)6K M.*_Y?'VM]X#LB_.!H8I$E\ZD#$!-B$$T#FIB6K*D,&)$]@)6>R=?Q&WN5)89 MW&MB!8K<_U7FD;PRMOPVVY?7=(WBI@W4F2-Z;P;!/TO>>2FQLG0)4)-9=38;G!X M"4DMPD8&9RYN<%(-FSC>A@EX-U 5W_&5+7#$;D/4LS9Q1O&ANP^+"5=JYP7K M\6<>H5@'Y0WQG/7\36_;J"3?'(*:\Z\.@66;WD^ MD0$(A[%4#/[93_RA4_* M_B=8;!/B&@UB& U4!T.>,8MY'%=&9*PD0/"!0X@4#Q.2$B2OJ8/82T98;0)Y M@*0LFW%)2Z$2Z+,]/2HZE M#,%6D4-QCB%&U!&T$0C!L$AC!K1+.2H44LK:DY-U+'9G0#Y^",ZS-W),R@9N M,BAY5!XYCMCP=)]T$.7FZ>EOP3(W[G39L,@A-L"&(0'C6( M[LG'QP]B[2&ZM2U&Y,-G7G3KW7697SF!#(A@L(,OA]O3"S?N(?!&;-2]!D0? M/P"I8J1!<9<:+GR)$4,PYU*R#;-PO/G0X'1F=W3 !T@BIN_A$/P3L;YWX#WR M0*O5^_A!IM36\B;Q]C2C'V(=^=CY^[2@09@& DPA.@D8VT 2R I'))A-_=\SK<XWMG3:K9>A[Q!'O8]MEU9>1:2WQ<4OKWI9%)[+_%C(,R>N+JDGENI&*\P MF]*HQA@2/O 47'QL55_&TPIAFD-M>2O5JQNL33[TMPEG$]9" ]@3\?7GA/ID M4_6^T'/#,'+?[D;&A4)220WX4#PUG8)( &^<8KWN^C=%SN:2T/(2-RJ.D.I+ MB6GJ#VSW/=MX^FQ=QY/O:Z'KL4*X^EX(?R^$OV(A?#VOI%BGFL;^^HS:R7FI M<]&*_YUPJQ>>_G #1=@AC,!QI$'0_0=,D &[V/'[KNE02R-./U$)64D0F#)#P\X@/+ M 7NBOU=&WG+ 9KEOAO!)>/!%R1LQ$5@_@4)A0TY%#V]L&$SR'GD6K[L;IQT MOHH(; *?WQ@-[^OX-FAX [4"\;XMO>A7,A??NO6:[#Z:%/]( ?/9!*99VJL< M6, TCAHI=&K9-]1DKZ[K?_R\^NL0)HYN/RPD+W\ Z;E71DJ9<.EY%XP_39A\ MA&E#):,\H*3GDC,[E.1>=^ML;(UQ76>,_MS1VNP^:LC=)59TK]-\+S"NN\"X MIB.J"S=:IKN6/I&*,N!#XW!>"MJ$[\L7]1716!_OHUI%_G*5R1]=R[9G52O[QAWVA[-_NS?O9%5ULJ MR9ZV_L_BZD[+.CD:#'^;O\WRT4G=/,>[KG?R\.6G^:I[=.(WT]4Z^V>T>-VJ7SE"[/FE^ MT?JY3KN6VZMV[I7.V>0:[[4:=05?U/%)26DV3^PLO?Q9MY0:.].UQJ5>;:M# M:Y(=YHTOO9LS9@']A>.C9LX>'5ML4*W6U=:7,;1Y+]C@C\AUJ-#RD" E*E,3#W*5)R:9'!T>45N'] MLE'H+@ UZLM]$(1__;[,K.IN'*0E+>F!/+)LR02ZJ[*R,E\>E5DZG)9Q=-3M M'$Z-#NG/TI:1.3KZF*XOZK07RW>JR-B%$($9[:V-3J%=FIMZDL4YZ\D%/79C#N.L__3#_PZ'VWL[VP-LPKVCXU#' MME#G4YW'.C!5:0,=%>HDS;.!>MK_^^&6/CHD>A:8-,9+T7S_CZAK,Q3$@911 MS9<1N$+?XX_LZ&Z6G]O)5"9]=C6U(UNJO;W!4*:^JSD#DY0FOW>[/)--ZG:6 M=^DX2=(J"3#87>UL[VQ#TA*=!%9'ZHTIJJ@LE$Y"]6-5V,04 MA7J7A;HTM[T/M[SP"YUT.Z?63-*>.@&'QVF>6*V^^]O3G>'P0+U*+TT\PH+W M>KQF6DW]Y0V2G>:ZM&FB[K\ZOC@]_L>^.CY]>?Y E6FHY^"2,#548\_!;B=W M+ 0!JIP:_$?\_LWQVR0A'K\P62GD/-P6>ICC69Y>6OI>JY%G?L7,'VPJY[V. M;B9UI_D 0F&2!+O[RP!RD4<0CW-L$=B,.8CI)U-KQNK9E0FP[Y=&O1Z/;8"= M2F?[X+WI=G1NE+D*+,B%S*JIQ@+?7:CW:1Z%+TU8 M*)NH<15%*L @>1K1JM,J5Q>_OOSEV?D92618!:5*TAD$69Q'-4R/;U/2P)5LGQPP*3PX*%9K %D0/_8L!_N?LY<]GZM7IL9I- M;3#E]6I58@=-JPJ+*C'^'&ZMTFPT),!7G(A[=CABV8I,M MV^TS$[\>,R-NCZ7VR.%%MW/?9+!;V33'[P_46?)/:"UTZ'#+;BR+7\-Q^*4" M# S%%/<<[CL@4 E&6@6/'G#T_4NHY$0G!#AQ6A)J.4:PTLO>?9>;R8%HOWQP M#8NZG>W!PWC"BO[YHZCMP7 7HS@(!*Y.\[2:3)4EEX0B"E7HR+![$AB"?\*< M=X,+@"4O2("V() =IT%5\(ORBAGC)?R4RDM3^,S]#+8TR.$Q8^TZB@SVIRC! M[,R$5I>Y!C<7^S55 1BF;S@OY<@"/M&U3NAW@GDQ(;X48#^-7*^8& M!#+!,\!P;7&(MM=!F;)K-6RY5F3 ^''@*9F?.7"VR%+,.8H,6XYZRFYG84Y0 MX[;CJQ/V6=1A>[L=VB&=S&OC>ER!Q7#327F\0CV#BB'*_=GHJ)SVG)6E[=7! M;Y7-L;NC.;MKA57/6RX92?$O56)Z[,78I#(LOK,T_^#%O]L1TSJI(EVF$$+H M1T#N]_ $EL2!_ Z O[8E."6U[NQS8L2CD0T)C$CYV9C9>PNX_';MT?LJ\$:)3I* MK])%A-QD6\2Z B>4G(6SD(6+"".C"PXL8XQNX>JH8%ZF'RA#Y*8",%Q24@)A=0Q3J (3146; M5&A@:4$^^UO@+7FUP!'-GI%#FD+,I Y#]L2@B45 []@QC*+0#B<)KYI0\@G0 M?4X/!!$L94#/8\'$4BP902N\K)7I9?%^7R@^AS<85'F.+Z-YM\.)&3N>DQ" M)P0KE'<(T@JNJY_/90R %1C"6_ 6V;PP9WKQ)&_#HA0MH!;L=I2"## E[41T5\WB-X_?;XQQ?/U,FS%R_.CT]/SU[]],.] M[7O\\\7Y\8G_^>+MKR^>_7!O\5SI[1O\=^J_6STB6#J'\D2_/06[Z-TMGOMH M81GM Z3VV=%?6- VR(K?:@[;%@C#*9@ .#%X7NKV(?%DQAKBG0 M)ZMF"9L-S830K 3TP=2\3HRD,0WLE]#;#NQ@.B]I*4#-BE.>;,(1ZHF?>YH/ M8"9--C6)^EE/R2-UEH(2M>PQ6N:,R1_TO'$ !2TKOF*9%M:S:ME7EX,( EZT MU;<*V7?BYGDYOETW[TY(I5BCVWE=E45:P>>'C#[7@8W@ VVRE_HK?!JH0,H! M&!T#X;G(N/Q2TO<_0Z@-NQ8^^%\)O6;3E#R%=):0OE#I*%/?&3X(>>#C8V-[>XLX7'+1/)Y?K?C#_17SO(WF?S-MKQ>/81*4KIN M9U$YOGDT>*@P>$0&@_3MF]W!7OU!4P&0&Z\W-Q< [&P/]WH^;X.H,)I+M-;M M> TE!:KQA8SYHK(^^59."REND?\3,TN9=_!@+1X F8 6B/!:QYH>6[!@#RZ+ MJ";9'#O#5I2VLG&,X^6J.'+YWSQ3 MTBEGF_E,PN$N>PFY\QP*0D0?N_;JC*_$^0*T'CH=Y.)Y\*2&>OANB#W 31:' MP.2E9AKIN*5YRG-PL'%*L-DJ>@%YPB[TA,J)@2=(-3BT#[J5OK^4*H2D:/*- M\L:GJ:82P[L( ;N#I\L0\+#;<9\L*?.FLG&S-QF&#$A&"6$)9)H,7[VIZS9F M.'CB-T;6Q[OSL(78GPS0W[MY05I M41:^)(<1L-OQ%3D T]!R^<)7J?HLZDYTX23*_%;92]@SRDZZ$B=#)F>\IGZ/ MCR.7Y&QG\,B+E$NNZA@N>XGM#*(*@;?8*RJWDF1MPE.6UQB'WXVN=N#G5V;4#JW#(]N9:#;D[N_[3U^LM<(WN<1>)L4/3\]EFSM1_W# MN@Z88IM!!3NK)Z;*'Y@NKG*KS.DWDM.O(OM59/\_%%%YP/P3A/;C#]'H29>8 MY8,]LH,KAX<'-,)7V?XJVW>AOGJ9^]B?_Z%/(7D><^21/$2H;KA$YT M%&TRN;X+;X983$T1Q2/(#VKZ$;M'XL9%E)F:F5&@\8A/4[Q,DU#/>RLM:Q2; M[NQO;ZLLA@X'7)1#=+A,5DJETG12[$J]ZX8T-KJ9H3P8[.S-[6E2A;I-57HS M0T3658@4M4HO&F4OZO:T5KI"CXBY]:AMQ&*K'9%07LK2RXEUOQ]_* MS][V+]O\@=_SMRFS!0YU*47!6F18\Z/WNEDDJ:$9S2;ZP?<,TK'ZAUN-M9WZQ^VTO[4Q9UW246[0L9Z)1%%5R9%Y5S-;)IMO!T7>G=',9Q M/Z/T"#JWU1='-IE4^SM]YH_CNQWJTW;EEF6K0TS3>5W/'? TO8_01PR:VI + M,,*T,')6:'/I.J.Y;#*.=!S+!W#928L6.FKJHH _:JIMFCRU/_V\E!(NU\K. M3GY5U.UFAAOLDF"^6/.H@PI>O>O>#$"PM!FUUT=1A,ZF\TA?V<*!TG*;K&NU MPDM+]#5GE3W)B_36UUXNL8ZVN-48( 6BM"HJ&H4L<2WLVM:H=2U1 W^;@RT6 M=K\ITF]7L?AMK>F#*!#-"S)^K28(0]L;[_898Q=5,*6PRN527[7 MU"-53F-I+SQY?7[:&($U0E)4H\*&5N=4+DBG JV"P1YD)1A(01Y]5-0EBZYM M-Q.>Y=7$U;;X^I0$V^\>Y6^E^'=:07OYN4M#WW++"\D71 Y1;F9+OA[#5<[0 M6JF$9^[2+FX*O%K7UKCN3+KZ(*8HV5G3!2MUJ^;CS\+DOX1=<2C\W%W$\2*E MCJ.); OKQ!=I7*2>+N.F,=]9127T$/O"7SK2C]Q:BWJMSI5B^8R-3EP[#_UX MGG/O%68$7$G]V O\,1%#]892G;$ZEKM.AGM[NX-NYX)0X(;)7.4 AD_9O])< MZ\(TP\V2CGK8(9MI\4W)2TM*WP!-&&^)!Y.4%5(@LN BNW%55OEBGQRT)U2VMQ,N,_?M"^265/F+'4[9%3(4S;@4$K% MCOB:^.Y;)99AE7CM3ZS<8MKTFCB+TKD10*>6688W_E_ W12RU.MV((T5<0HO MY\62GU&?'AR(':0&PHDK9JPYM'PCC3-\/N:XOI^WVWGEK+\] MA.*CZ:4!]8B+Y;DNO^W'F5:)U9J)W7U;GSLSU[5+FPD7FQ*\6VE:;#7WW.;*3S.QG[BI M-:X2](A6DHO,+:-^BFZGJ;>@R65Q;@F?-)N?(2<\"JBA&4.&3<=7@57.@[I2UK8R5-!*[HW:YPJH5V#0..;W?@"EFOJG3JZ>\0[]N M0<0]]GN%GH.VS9"+KYK-PDBC?XH0%?[NKMIJL3USQPQ3"^L22U6 ^[H^]%@& M40]2'@MJIYFE8[U))%M57Q?B(J)EMJ]:C?52W(+WIF%][*.;MI'Q. M$D;VC MFVD$A@_<_2)B@_@EX<>XMJ_48C>CNU.:"(8$B#C,YE2V;^'9A88" AU2:%?; M[^,&:JGS@<-BD$VN3>4J^@\6=(>U!,W["O<+M81X83T)M'L38%*2T1; MFTZ%N"ONP/*YUZIC1 Y5FD24C* .AN8MFTC#YH MS>M]4EX622A"P!'YAP /!'B:+Q7]&%AS?'.!>I.E($5K\(DXO' S2=N1X?L6 MFHQL>1U!C7M"[I.T[U!RELAT?K5\OWHQT?+UG3;?X\J!.97X4F,6W3R%R5\8>KM7DR.D+M+L\CIK&;/B93$.7[,9 M@L/>$5_8AJ5YW86'2[-)DFJ-/^KN4B(QH-+FJ]+4=Q7VG)3+91T!I4" +S!5 M='JM*;'3>K#1;#(FDM9IH08^;"5YBG8O4[/$:UQF1V)/+M?)J?:E<(?@2]=& M$'82JKG RBN,IP>:Y -J \(U!3!U(15)#!/#52V(,/!/ M&W;\>FS*J0T@2C5X YDEJ\=L$YO?-!?5#:2\$47A,*U%!3Y5.4";-P0=R]! M?7N&%GP)SC/K:A(1+C#K75;B+\A1'*!K0'93+IN M?N[Y6+0Q%/I3QW#+UOA4;.&]1@K^K.COV)(XMGS(5H*"AGMVA4@UF1A"IEH" ML!"&'=(1FR_ZN?XF7A*4D8F'B&+ ML,U-WCBS,[[^9;GE&,SBU3Q_V!AEVIJLA,4P_C&A-%3!5+ MZ7*@6\OY.L>DV0@@"YX,#9V!<4S+J0\1(A>.<3^D1*;M.)LVG-()VG=PMU)# M:HT97B?1,S)D=!MU25M!6K.8&#&:QF0CYF^SK2MXG./.^,-WA8E#P;:"WW V M)1[91'NOJO8^H/$T-3D>JPZ'N!CMG7" EC8Y-U%WGNUZU\/=@L=[Q"4>I/[!*I:/(9Q I M:G.55[F'0ZR;S_ZC^7+2AA9"5D]LB0#XC8X=2P#)YICZ;ULYN\#F017C07;Q M8%CX9BX^TY:$AS]L<9=UM=!ZH$[J3E='P#I_MK?JT#*D+)B""86DAI0+KY'% M\V>=_N3)XYP(%QD"!R@MY'MVT@Z*.&^4)"*N#,5@\W-*TPZW^W^O3Z?F?-\# M-P2*N)R:P#4%\MVBU KHKY>FD))+:LL5W)5WB03GUK&TN.,H1+YI,J$+4& 6 M"S6'= M0A!*$!G1':<@2&O'UW$X]\W:= 1_]4\ VY9M=7$X3,WY/=7PCOD@+ M)E&F=[4CL]EL4)A@,$DO!V0*2%2=N17.P4L"UL7'!)*S5C3_0]R_G@.(OJGS#P@6 M8)6!35\<]11WG_)52F3"SY)+\K-S!)\N7?/%+>H['=,AN"\"$;>U2ERP M\^6MYR.J7+ZX-=U_NOOT0;=#Y61/]G:'7QS]\5@T_K\T;XYD.ZFP\HM;R>U7 M5OX%R?Z([JB'!^JUW BZKUY0F\9=-DO=R:V-_[I]H[^=S?VM;(=;[B]R^S]0 M2P$"% ,4 " 6@VE1Y?25OTD# "V# $0 @ $ M861M<"TR,#(P,3$P.2YX&UL4$L! A0# M% @ %H-I4;#&P_-A!P 3ED !4 ( !J X &%D;7 M M,C R,#$Q,#E?<')E+GAM;%!+ 0(4 Q0 ( !:#:5$W&N34'Q, #R0 2 M " 3P6 !A9&UP+3AK7S$Q,#DR,"YH=&U02P$"% ,4 M" 6@VE1C4$H2@H8 #1;0 "@ @ &+*0 97@Y.2TQ+FAT 7;5!+!08 !0 % #T! "]00 ! end